Psoriasis Clinical Trials in Austin
View 11 new treatments for Psoriasis in Austin, TX, and nearby areas, such as Round Rock. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Austin + 1 more
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 6 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Bimekizumab for Psoriatic Arthritis
UCB Biopharma Clinic, Austin + 1 more
This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
UCB Cares
Study Director
Tildrakizumab for Psoriatic Arthritis
Sun Clinic, Austin + 1 more
This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Apremilast for Pediatric Plaque Psoriasis
Amgen Clinic, Pflugerville + 1 more
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
MD
Study Director
Upadacitinib for Psoriatic Arthritis
AbbVie Clinic, Austin + 1 more
The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo for the treatment of signs and symptoms in adults with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to biologic disease-modifying anti-rheumatic drug (bDMARD). The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants who have completed Period 1.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
AbbVie Inc.
Study Director
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Austin + 1 more
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Waitlist
Phase 3
Est. 6 - 12 Weeks
AbbVie Inc.
Study Director
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Pflugerville + 1 more
The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Bristol-Myers Squibb
Study Director
Ixekizumab + Tirzepatide for Psoriasis
Eli Lilly Clinic, Pflugerville + 2 more
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Guselkumab for Psoriasis
Janssen Clinic, Pflugerville + 2 more
The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and symptoms of psoriasis.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Austin + 1 more
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Page 1 of 2
Frequently Asked Questions
Explore related conditions